Most GLP-1 providers
Typical dose-based pricing
+$130/mo more at the top dose
A once-weekly compounded semaglutide injection, prescribed by a provider as part of a personalized treatment plan.
4-Month Money-Back Guarantee
Try Renlo risk free. If you follow your plan for 4 months and don't see progress, you get a full refund.
Billed monthly. Cancel anytime, no fee.
You could lose up to
Semaglutide is a once-weekly injectable GLP-1 medication that helps regulate appetite and blood sugar, supporting steady, sustainable weight loss when combined with lifestyle changes.
Renlo patients report:
Fewer cravings and less thinking about food throughout the day
Feeling full faster, with fullness that lasts longer after meals
Steady progress that builds momentum, not a crash-diet rebound
Most GLP-1 providers charge more as your dose increases. Renlo doesn't.
Typical dose-based pricing
+$130/mo more at the top dose
Flat monthly price
$0 increase, at every dose
Price comparison illustrative of typical dose-based pricing in the GLP-1 category. Renlo's compounded products are prepared by a licensed 503A pharmacy.
No insurance, no waiting rooms, no referrals. Get started in minutes and receive your treatment in days.
Answer a few questions about your health and goals. No appointment needed.
A licensed U.S. provider reviews your intake within 12 hours and prescribes treatment if you qualify.
Your medication ships from a licensed U.S. pharmacy directly to your door, free and fast.
Your care team stays with you with unlimited check-ins, adjustments, and answers at no extra charge.
Semaglutide is a once-weekly injectable GLP-1 medication that helps regulate appetite and blood sugar, supporting steady, sustainable weight loss when combined with lifestyle changes. Suitability is determined after a licensed provider reviews your intake. Clinical results reflect semaglutide, the active ingredient - not a guarantee. Renlo's compounded semaglutide is not the branded product studied in this trial, and individual results vary based on your body, dose, and adherence.
1 Average results in the STEP 1 trial, New England Journal of Medicine.